Mesothelioma and Small Cell Lung Cancer  by Tsao, Anne S. & Heymach, J.
Mesothelioma and Small Cell Lung Cancer
Anne S. Tsao, MD, and J. Heymach
In the mesothelioma section, two presentations were given.First, Dr. Donington delivered an overview of the most
common targeted pathways and agents studied in malignant
pleural mesothelioma (MPM). As described, the current
front-line standard of care for unresectable MPM patients
remains platinum pemetrexed, and numerous targeted agents
have been investigated in combination with front-line che-
motherapy and in the salvage setting. Although mesothelioma
has the highest secreted levels of VEGF of any solid tumor,
adding bevacizumab to cisplatin-gemcitabine did not improve
PFS or OS in the ITT population from a large phase II random-
ized trial.1 Nevertheless, targeting the VEGF pathway may still
be relevant in MPM, because patients with serum VEGF levels
below the median who received bevacizumab had a superior OS
(p 0.028). In the salvage setting, several phase I and II studies
that targeted angiogenesis (VEGFR, PDGFR), EGFR, TRAIL-
R1,2, Bcl-2, tRNA, immunotherapy, and mesothelin were dis-
cussed. In general, only modest results from these studies (neg-
ative results from the monotherapy EGFR tyrosine kinase
inhibitor and imatinib mesylate studies) were reported. In terms
of promising new agents under investigation, a large interna-
tional phase III trial of vorinostat versus placebo in second- and
third-line therapy was discussed.2 This trial has completed its
accrual of 660 patients and will have the results presented later
this year. If positive, this will potentially alter the treatment
landscape in the salvage setting for MPM.
In the second presentation, a phase I neoadjuvant da-
satinib trial being conducted at MDACC was presented. This
study is the first neoadjuvant targeted therapy study to be
conducted in MPM and consists of tissue harvesting from
multiple areas of the tumor at two time points, before and
after 4 weeks of neoadjuvant dasatinib therapy. The prelim-
inary results suggest that Src kinase Tyr419 IHC overexpres-
sion may be a valid biomarker at baseline that predicts for a
response to dasatinib therapy and is a consistent pharmaco-
dynamic marker.3 A phase I trial in the unresectable MPM
patients using cisplatin-pemetrexed-imatinib mesylate was
presented which seemed to stabilize the cancer more than
achieve a response. Nevertheless, this trial provided the
rationale for SWOG 0905, a phase I/II trial in chemonaive
MPM patients evaluating cisplatin-pemtrexed  cediranib
(VEGFR, PDGFR inhibitor). S0905 is open for enrollment
and has completed the phase I portion and has established the
phase II cediranib dose as 20 mg po daily.
Small Cell Lung Cancer
Although standard therapy for extensive stage SCLC
remains chemotherapy, several new therapeutic approaches
for SCLC are currently under investigation.
VEGFR pathway inhibitors
SCLC is known to overexpress ligands for the VEGF and
PDGF receptors and frequently harbor c-KIT amplifications.
Cediranib, an inhibitor of all three receptor tyrosine kinases, is
being investigated in combination with etoposide and cisplatin
(EP) chemotherapy. In phase I testing, cediranib demonstrated
promising activity in combination with EP, with a median
progression-free survival of 8.9 months and a objective response
rate of 70%, results that compare favorably with historical
controls. A phase II/III trial is currently in development. In phase
II, promising activity has also been observed for bevacizumab in
combinations with EP4 or irinotecan/carboplatin.5
BCL-2 inhibitors
BCL-2 is frequently overexpressed in SCLC and is asso-
ciated with resistance to chemotherapy-induced apoptosis. The
BCL-2 inhibitor ABT-263 was tested in patients with SCLC and
other solid tumors. Among 29 patients with SCLC or pulmonary
carcinoid, one patient had a durable partial response, whereas
eight had prolonged stable disease. Progastrin-releasing peptide
was identified as a surrogate for Bcl-2 amplification. ABT-263 is
currently undergoing further testing in combination with EP.
Other agents
Amrubicin is an anthracycline inhibitor of topoisomer-
ase II. Randomized phase II studies in refractory SCLC
suggest that it may have comparable or greater activity than
topotecan. Phase III studies of amrubicin monotherapy in
second-line SCLC is currently in progress. It is also being
tested in combination with cisplatin for first-line SCLC.
SVV-001 is a picornavirus with selective tropism for
tumors with neuroendocrine features. Phase I testing suggest
that it has activity in SCLC. A phase II trial in SCLC patients
conducted by the North Central Cancer Treatment group is
currently in development.
Future Directions
The development of novel agents in both mesothelioma
and SCLC is promising. Several classes of agents have
demonstrated preliminary benefit in these notoriously diffi-
cult to treat thoracic tumors. For both tumor types, the results
Department of Thoracic/Head and Neck Medical Oncology, M.D. Anderson
Cancer Center, University of Texas, Houston, Texas.
Disclosure: Anne S. Tsao reports an honorarium from Genentech and Roche,
and research support from Merck and BMS.
Address for correspondence: Anne S. Tsao, MD, Department of Thoracic/
Head and Neck Medical Oncology, University of Texas M.D. Anderson
Cancer Center, 1515 Holcombe Blvd. Unit 432, Houston, TX 77030.
E-mail: astsao@mdanderson.org
Copyright © 2011 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/11/0611-1825
Journal of Thoracic Oncology • Volume 6, Number 11, Supplement 4, November 2011 Santa Monica Supplement
Copyright © 2011 by the International Association for the Study of Lung Cancer S1825
from early trials using antiangiogenic agents are noteworthy;
and additional larger prospective trials will hopefully define
their role in mesothelioma and SCLC. The standard of care in
salvage mesothelioma may change depending on the final
results of the phase III vorinostat versus placebo trial. Both
fields require efforts to cultivate predictive biomarkers and
improved screening modalities.
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